Julio Duarte, Pharm.D., Ph.D.
Assistant Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-8132
Business Email:
juliod@cop.ufl.edu
About Julio Duarte
Julio Duarte is an assistant professor in the Department of Pharmacotherapy and Translational Research and the Center for Pharmacogenomics and Precision Medicine. He received his Pharm.D. as well as his Ph.D. in clinical pharmaceutical sciences from the University of Florida. He was Assistant Professor of Pharmacy Practice at the University of Illinois at Chicago (UIC) until coming to UF in 2015. While at UIC, Dr. Duarte was the Director of the Pharmacogenomics Laboratory and Co-Director of the University of Illinois Hospital Personalized Medicine Program. Dr. Duarte has served as a reviewer for both NIH and U.S Department of Defense study sections. He is also an elected fellow of the American Heart Association and has received awards for his research from both UIC and UF.
Accomplishments
Fellow
2017
·
American Heart Association
Outstanding Clinical Research Award
2017
·
University of Florida College of Pharmacy
Hans Vahlteich Research Scholar
2013
·
College of Pharmacy, University of Illinois at Chicago
Research Profile
Dr. Duarte’s research primarily focuses on: (1) the biological mechanisms underlying pulmonary hypertension development in patients with with left heart failure, and (2) the clinical implementation of pharmacogenetic testing, particularly in medically underserved patient populations. His NIH-funded laboratory conducts translational research attempting to discover genomic predictors of drug response, as well as using genomics and transcriptomics to identify novel targets for future drug development.
Publications
2021
County-level longitudinal clustering of COVID-19 mortality to incidence ratio in the United States.
Scientific reports.
11(1)
[DOI] 10.1038/s41598-021-82384-0.
[PMID] 33542313.
2021
IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias.
Blood.
137(9):1208-1218
[DOI] 10.1182/blood.2020005944.
[PMID] 33181835.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
109(3):705-715
[DOI] 10.1002/cpt.2039.
[PMID] 32897581.
2021
Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines.
Clinical and translational science.
[DOI] 10.1111/cts.13032.
[PMID] 33955180.
2021
Pharmacogenetics to guide cardiovascular drug therapy.
Nature reviews. Cardiology.
[DOI] 10.1038/s41569-021-00549-w.
[PMID] 33953382.
2020
Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
Journal of cardiovascular pharmacology.
75(3):250-258
[DOI] 10.1097/FJC.0000000000000779.
[PMID] 31895871.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
The pharmacogenomics journal.
20(5):724-735
[DOI] 10.1038/s41397-020-0162-5.
[PMID] 32042096.
2019
Determinants of Cytochrome P450 2D6 mRNA Levels in Healthy Human Liver Tissue.
Clinical and translational science.
12(4):416-423
[DOI] 10.1111/cts.12632.
[PMID] 30821899.
2019
Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-55700-y.
[PMID] 31862991.
2018
Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.
JAMA.
320(16):1670-1677
[DOI] 10.1001/jama.2018.14955.
[PMID] 30357299.
2018
CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue.
Clinical pharmacology and therapeutics.
104(5):974-982
[DOI] 10.1002/cpt.1032.
[PMID] 29349771.
2018
Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.
Pulmonary circulation.
8(2)
[DOI] 10.1177/2045894018773049.
[PMID] 29718770.
2017
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
Clinical pharmacology and therapeutics.
101(5):675-683
[DOI] 10.1002/cpt.558.
[PMID] 28032893.
2016
Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure
Journal of cardiac failure.
22(9):692-699
[DOI] 10.1016/j.cardfail.2015.12.016.
[PMID] 26721774.
2016
Clopidogrel pharmacogenetics: from evidence to implementation.
Future cardiology.
12(5):511-4
[DOI] 10.2217/fca-2016-0045.
[PMID] 27539287.
2016
Implementation of Inpatient Models of Pharmacogenetics Programs
American Journal of Health-System Pharmacy.
73(23):1944-1954
[DOI] 10.2146/ajhp150946.
[PMID] 27864202.
2016
Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.
Clinical and translational science.
9(5):233-245
[DOI] 10.1111/cts.12404.
[PMID] 27214750.
2015
Genes Affecting Warfarin Response-Interactive Or Additive?
Journal of clinical pharmacology.
55(3):258-260
[DOI] 10.1002/jcph.425.
[PMID] 25385663.
2015
Genetic Associations With Warfarin Response in Patients Receiving Genotype-Guided Dosing.
Clinical Pharmacology & Therapeutics.
97(1)
2015
Pharmacogenomics of hypertension and heart disease.
Current hypertension reports.
17(9)
[DOI] 10.1007/s11906-015-0586-5.
[PMID] 26272307.
2014
Barriers To Implementing Pharmacogenetic Testing in An Urban Population.
Pharmacotherapy.
34(10)
2014
Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes.
Expert review of cardiovascular therapy.
12(11):1289-303
[DOI] 10.1586/14779072.2014.970180.
[PMID] 25340283.
2013
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
The pharmacogenomics journal.
13(3):257-63
[DOI] 10.1038/tpj.2012.4.
[PMID] 22350108.
2013
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
Journal of hypertension.
31(4):698-704
[DOI] 10.1097/HJH.0b013e32835e2a71.
[PMID] 23353631.
2013
Feasibility of implementing a comprehensive warfarin pharmacogenetics service.
Pharmacotherapy.
33(11):1156-64
[DOI] 10.1002/phar.1329.
[PMID] 23864527.
2013
Personalized medicine in cardiology: the time for genotype-guided therapy is now.
Future cardiology.
9(4):459-64
[DOI] 10.2217/fca.13.35.
[PMID] 23834684.
2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-56.
[PMID] 22440088.
2010
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
Pharmacogenetics and genomics.
20(8):516-9
[DOI] 10.1097/FPC.0b013e32833b5958.
[PMID] 20555294.
2010
Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics.
Expert review of cardiovascular therapy.
8(6):793-802
[DOI] 10.1586/erc.10.27.
[PMID] 20528637.
2010
Sirtuin-1 Gene Expression Correlates With Systemic Cytokine Concentrations in Atorvastatin-Treated Healthy Subjects.
Clinical Pharmacology & Therapeutics.
87
2010
Yeats4 Gene Region Polymorphisms Associate With Antihypertensive Response To Hydrochlorothiazide in African Americans.
Clinical Pharmacology & Therapeutics.
87
2009
Hydrochlorothiazide Modulates Cardiometabolic Gene Expression in Human Endothelial Cells.
Clinical Pharmacology & Therapeutics.
85:S73-S74
2008
Leukocyte Expression of Atherosclerosis-Related Genes in Response To Atorvastatin Differs By Cyp3A5 Genotype.
Clinical Pharmacology & Therapeutics.
83
Grants
Jul 2020
ACTIVE
Together Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Nov 2015
– Mar 2020
Improving treatment personalization for pulmonary hypertension associated with diastolic heart failure
Role: Principal Investigator
Funding: NATL INST OF HLTH NIGMS
Education
Ph.D.
2010
·
University of Florida
Pharm.D.
2006
·
University of Florida
Teaching Profile
Courses Taught
2017-2018,2020
PHA5878C Pt Care 3: Cv and Pulm
2020
PHA6910 Supervised Research
2017,2019-2021
PHA7980 Research for Doctoral Dissertation
2017,2019-2021
PHA7979 Advanced Research
2020-2021
PHA6935 Selected Topics in Pharmacy
2017-2021
PHA5012 App Personalized Med
2019-2021
PHA6135 Clinical Applications of Precision Medicine: Pharmacogenomics
2018
PHA6449 Pharmacogenomics
2018,2021
PHA5876C Pt Care 8 Complex Pts
2017
PHA4914 Undergraduate Research in Pharmacotherapy and Translational Research
2020
PHA5040 Pharmacogenomic Literature Assessment
2021
PHA6894 Introduction to Graduate Studies
Contact Details
Phones:
- Business:
- (352) 273-8132
Emails:
- Business:
- juliod@cop.ufl.edu